Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29 2017 - 8:00AM
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced the grant to two employees of
inducement stock options exercisable for an aggregate of 37,000
shares of Albireo’s common stock. The stock options are exercisable
at a price of $26.12 per share, the closing price of Albireo’s
common stock on December 28, 2017, the grant date, and were granted
as inducements material to each employee’s acceptance of employment
with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has a 10-year term and vests over a four-year
period, subject to the employee’s continued service with Albireo
through the applicable vesting dates. The vesting schedule for each
stock option is 25 percent on the one-year anniversary of the
employee’s start date with Albireo and 75 percent in equal
installments on the last day of the 12 consecutive quarters
beginning with December 31, 2018. The stock options are subject to
the terms and conditions of Albireo’s 2017 Inducement Equity
Incentive Plan.
About Albireo Albireo Pharma is a
clinical-stage biopharmaceutical company focused through its
operating subsidiary on the development of novel bile acid
modulators to treat orphan pediatric liver diseases and other liver
and gastrointestinal diseases and disorders. Albireo's clinical
pipeline includes a Phase 3 product candidate, a Phase 2 product
candidate and a product candidate for which an application for
regulatory approval has been submitted in Japan. Albireo was spun
out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key
operating subsidiary is located in Gothenburg, Sweden. For more
information on Albireo, please visit www.albireopharma.com.
Investor Contact:Hans VitzthumLifeSci Advisors,
LLC.212-915-2568
Media Contact:Heather Anderson6
Degrees980-938-0260handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2023 to Sep 2024